Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.

Jennings CJ, Murer B, O'Grady A, Hearn LM, Harvey BJ, Kay EW, Thomas W.

Br J Cancer. 2015 Jun 30;113(1):69-75. doi: 10.1038/bjc.2015.187. Epub 2015 Jun 9.

2.

p16 Protein and gigaxonin are associated with the ubiquitination of NFκB in cisplatin-induced senescence of cancer cells.

Veena MS, Wilken R, Zheng JY, Gholkar A, Venkatesan N, Vira D, Ahmed S, Basak SK, Dalgard CL, Ravichandran S, Batra RK, Kasahara N, Elashoff D, Fishbein MC, Whitelegge JP, Torres JZ, Wang MB, Srivatsan ES.

J Biol Chem. 2014 Dec 12;289(50):34921-37. doi: 10.1074/jbc.M114.568543. Epub 2014 Oct 20.

3.

Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.

Holm R, Førsund M, Nguyen MT, Nesland JM, Trope CG.

PLoS One. 2013 Apr 8;8(4):e61273. doi: 10.1371/journal.pone.0061273. Print 2013.

4.

Methylation of tumor suppressor genes in ovarian cancer.

Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N.

Exp Ther Med. 2012 Dec;4(6):1092-1096. Epub 2012 Sep 18.

5.

Tumour suppressor genes in chemotherapeutic drug response.

Lai D, Visser-Grieve S, Yang X.

Biosci Rep. 2012 Aug;32(4):361-74. doi: 10.1042/BSR20110125. Review.

6.

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ.

Clin Cancer Res. 2011 Mar 15;17(6):1591-602. doi: 10.1158/1078-0432.CCR-10-2307. Epub 2011 Jan 28.

7.

Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk.

Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Phelan CM, Anderson S, Rider DN, White KL, Pankratz VS, Song H, Hogdall E, Kjaer SK, Whittemore AS, DiCioccio R, Ramus SJ, Gayther SA, Schildkraut JM, Pharaoh PP, Sellers TA.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):935-44. doi: 10.1158/1055-9965.EPI-08-0860. Epub 2009 Mar 3.

8.

Role of p53 and Rb in ovarian cancer.

Corney DC, Flesken-Nikitin A, Choi J, Nikitin AY.

Adv Exp Med Biol. 2008;622:99-117. doi: 10.1007/978-0-387-68969-2_9. Review. No abstract available.

9.

Consortium analysis of 7 candidate SNPs for ovarian cancer.

Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, Dicioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PD, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Cramer DW, Tworoger SS, Hankinson SE, Berchuck A, Moorman PG, Schildkraut JM, Cunningham JM, Liebow M, Kjaer SK, Hogdall E, Hogdall C, Blaakaer J, Ness RB, Moysich KB, Edwards RP, Carney ME, Lurie G, Goodman MT, Wang-Gohrke S, Kropp S, Chang-Claude J; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer), Webb PM, Chen X, Beesley J, Chenevix-Trench G, Goode EL; Ovarian Cancer Association Consortium.

Int J Cancer. 2008 Jul 15;123(2):380-8. doi: 10.1002/ijc.23448.

Supplemental Content

Support Center